EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Establishment of Novel High-Grade Serous Ovarian Carcinoma Cell Line OVAR79

Polina V Shnaider iD, Irina K Malyants, Olga M Ivanova iD, Veronika S Gordeeva, Ekaterina A Svirina, Natalya B Zakharzhevskaya, Olga Y Shagaleeva, Oksana V Selezneva, Alexandra N Bogomazova iD, Maria M Lukina, Olga I Aleshikova, Nataliya A Babaeva und 2 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252413236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Polina V Shnaider und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medi…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cystadenocarcinoma, Serous, Cell Proliferation, PTEN Phosphohydrolase. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation, Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-grade serous ovarian carcinoma (HGSOC) remains the most common and deadly form of ovarian cancer. However, available cell lines usually fail to appropriately represent its complex molecular and histological features. To overcome this drawback, we established OVAR79, a new cell line derived from the ascitic fluid of a patient with a diagnosis of HGSOC, which adds a unique set of properties to the study of ovarian cancer. In contrast to the common models, OVAR79 expresses TP53 without the common hotspot mutations and harbors the rare combination of mutations in both PIK3CA and PTEN genes, together with high-grade chromosomal instability with multiple gains and losses. These features, together with the high proliferation rate, ease of cultivation, and exceptional transfection efficiency of OVAR79, make it a readily available and versatile tool for various studies in the laboratory. We extensively characterized its growth, migration, and sensitivity to platinum- and taxane-based treatments in comparison with the commonly used SKOV3 and OVCAR3 ovarian cell lines. In summary, OVAR79 is an excellent addition for basic and translational ovarian cancer research and offers new insights into the biology of HGSOC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCystadenocarcinoma, SerousCell ProliferationPTEN PhosphohydrolaseFemaleHumansCell Line, TumorClass I Phosphatidylinositol 3-KinasesTumor Suppressor Protein p53MutationCell MovementNeoplasm Grading

Stichwörter der Autor:innen

cell linehigh-grade serous ovarian cancerovarian cancer

Substanzen

PTEN PhosphohydrolaseClass I Phosphatidylinositol 3-KinasesTumor Suppressor Protein p53PIK3CA protein, humanPTEN protein, human

Autor:innen und Institutionen

  • Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.
  • Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical and Biological Agency, 119435 Moscow, Russia.
  • Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.
  • Institute for Regenerative Medicine, Sechenov University, 119991 Moscow, Russia.
  • Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia.
  • National Medical Scientific Centre of Obstetrics, Gynaecology and Perinatal Medicine Named After V.I. Kulakov, 117198 Moscow, Russia.

ORCID-Profile: Polina V Shnaider, Olga M Ivanova, Alexandra N Bogomazova, Andrey V Slonov, Victoria O Shender

Förderung

  • Ministry of Science and Higher Education of the Russian Federation
  • Russian Science Foundation

Zitieren

APA

Shnaider, P. V., Malyants, I. K., Ivanova, O. M., Gordeeva, V. S., Svirina, E. A., Zakharzhevskaya, N. B., Shagaleeva, O. Y., Selezneva, O. V., Bogomazova, A. N., Lukina, M. M., Aleshikova, O. I., Babaeva, N. A., Slonov, A. V., & Shender, V. O. (2024). Establishment of Novel High-Grade Serous Ovarian Carcinoma Cell Line OVAR79. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413236

Vancouver

Shnaider PV, Malyants IK, Ivanova OM, Gordeeva VS, Svirina EA, Zakharzhevskaya NB, et al. Establishment of Novel High-Grade Serous Ovarian Carcinoma Cell Line OVAR79. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252413236

BibTeX
@article{Shnaider2024,
  author = {Shnaider, Polina V and Malyants, Irina K and Ivanova, Olga M and Gordeeva, Veronika S and Svirina, Ekaterina A and Zakharzhevskaya, Natalya B and Shagaleeva, Olga Y and Selezneva, Oksana V and Bogomazova, Alexandra N and Lukina, Maria M and Aleshikova, Olga I and Babaeva, Nataliya A and Slonov, Andrey V and Shender, Victoria O},
  title = {Establishment of Novel High-Grade Serous Ovarian Carcinoma Cell Line OVAR79},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252413236}
}
Kostenlos starten →